Ascendis Pharma As Stock Analysis
ASND Stock | USD 136.00 0.32 0.23% |
Ascendis Pharma AS is overvalued with Real Value of 67.52 and Target Price of 0.34. The main objective of Ascendis Pharma stock analysis is to determine its intrinsic value, which is an estimate of what Ascendis Pharma AS is worth, separate from its market price. There are two main types of Ascendis Pharma's stock analysis: fundamental analysis and technical analysis.
The Ascendis Pharma stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Ascendis Pharma's ongoing operational relationships across important fundamental and technical indicators.
Ascendis |
Ascendis Stock Analysis Notes
About 99.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 7.82. Ascendis Pharma AS had not issued any dividends in recent years. Ascendis Pharma AS, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark. Ascendis Pharma is traded on NASDAQ Exchange in the United States. For more info on Ascendis Pharma AS please contact Jan Mikkelsen at 45 70 22 22 44 or go to https://ascendispharma.com.Ascendis Pharma Quarterly Total Revenue |
|
Ascendis Pharma AS Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Ascendis Pharma's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Ascendis Pharma AS or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Ascendis Pharma AS had very high historical volatility over the last 90 days | |
The company reported the previous year's revenue of 266.72 M. Net Loss for the year was (481.45 M) with profit before overhead, payroll, taxes, and interest of 39.04 M. | |
Ascendis Pharma AS currently holds about 955.15 M in cash with (467.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 17.11. | |
Ascendis Pharma AS has a frail financial position based on the latest SEC disclosures | |
Over 99.0% of the company shares are held by institutions such as insurance companies | |
Latest headline from news.google.com: Ascendis Pharmas SWOT analysis stock faces growth hurdles amid pipeline promise - Investing.com India |
Ascendis Pharma AS Upcoming and Recent Events
15th of February 2024 Upcoming Quarterly Report | View | |
25th of April 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
15th of February 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Ascendis Largest EPS Surprises
Earnings surprises can significantly impact Ascendis Pharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2017-05-23 | 2017-03-31 | -0.75 | -0.83 | -0.08 | 10 | ||
2016-04-14 | 2016-03-31 | -0.46 | -0.54 | -0.08 | 17 | ||
2016-08-31 | 2016-06-30 | -0.69 | -0.6 | 0.09 | 13 |
Ascendis Pharma Environmental, Social, and Governance (ESG) Scores
Ascendis Pharma's ESG score is a quantitative measure that evaluates Ascendis Pharma's performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Ascendis Pharma's operations that may have significant financial implications and affect Ascendis Pharma's stock price as well as guide investors towards more socially responsible investments.
Ascendis Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Franklin Resources Inc | 2024-09-30 | 1.5 M | Amvescap Plc. | 2024-06-30 | 1.1 M | Adage Capital Partners Gp Llc | 2024-06-30 | 820.5 K | Vestal Point Capital Lp | 2024-06-30 | 750 K | Sofinnova Ventures | 2024-06-30 | 734.3 K | Camber Capital Management Llc | 2024-09-30 | 700 K | Citadel Advisors Llc | 2024-09-30 | 663.9 K | Ameriprise Financial Inc | 2024-06-30 | 660.7 K | Spyglass Capital Management Llc | 2024-09-30 | 652.8 K | Ra Capital Management, Llc | 2024-09-30 | 9.7 M | Westfield Capital Management Company, Lp | 2024-09-30 | 5.1 M |
Ascendis Market Capitalization
The company currently falls under 'Mid-Cap' category with a current market capitalization of 8.15 B.Ascendis Profitablity
The company has Profit Margin (PM) of (1.54) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (3.7) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $3.7.Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.59) | (0.62) | |
Return On Capital Employed | (0.73) | (0.69) | |
Return On Assets | (0.58) | (0.61) | |
Return On Equity | 3.30 | 3.47 |
Management Efficiency
Ascendis Pharma AS has return on total asset (ROA) of (0.2792) % which means that it has lost $0.2792 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (8.1843) %, meaning that it created substantial loss on money invested by shareholders. Ascendis Pharma's management efficiency ratios could be used to measure how well Ascendis Pharma manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 3.47, whereas Return On Tangible Assets are forecasted to decline to (0.62). At present, Ascendis Pharma's Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 374.1 M, whereas Non Current Assets Total are forecasted to decline to about 79.4 M.Last Reported | Projected for Next Year | ||
Book Value Per Share | (2.59) | (2.46) | |
Tangible Book Value Per Share | (2.67) | (2.53) | |
Enterprise Value Over EBITDA | (16.21) | (15.40) | |
Price Book Value Ratio | (44.02) | (41.82) | |
Enterprise Value Multiple | (16.21) | (15.40) | |
Price Fair Value | (44.02) | (41.82) | |
Enterprise Value | 6.7 B | 7 B |
Leadership effectiveness at Ascendis Pharma AS is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Operating Margin (3.70) | Profit Margin (1.54) | Beta 0.654 | Return On Assets (0.28) | Return On Equity (8.18) |
Technical Drivers
As of the 29th of November, Ascendis Pharma shows the mean deviation of 2.1, and Risk Adjusted Performance of 0.0136. Ascendis Pharma AS technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Ascendis Pharma AS information ratio, and the relationship between the downside deviation and value at risk to decide if Ascendis Pharma AS is priced correctly, providing market reflects its regular price of 136.0 per share. Given that Ascendis Pharma has jensen alpha of (0.08), we suggest you to validate Ascendis Pharma AS's prevailing market performance to make sure the company can sustain itself at a future point.Ascendis Pharma AS Price Movement Analysis
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Ascendis Pharma middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Ascendis Pharma AS. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Ascendis Pharma Outstanding Bonds
Ascendis Pharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Ascendis Pharma AS uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Ascendis bonds can be classified according to their maturity, which is the date when Ascendis Pharma AS has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
ASCENSION HEALTH Corp BondUS04352EAA38 | View | |
Dana 575 percent Corp BondUS235822AB96 | View | |
Volcan Compania Minera Corp BondUSP98047AC08 | View | |
Boeing Co 2196 Corp BondUS097023DG73 | View | |
US04352EAB11 Corp BondUS04352EAB11 | View | |
HSBC Holdings PLC Corp BondUS404280DR76 | View | |
MPLX LP 52 Corp BondUS55336VAL45 | View | |
Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
Ascendis Pharma Predictive Daily Indicators
Ascendis Pharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Ascendis Pharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Ascendis Pharma Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
6K | 13th of November 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
13A | 12th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 8th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
6K | 4th of November 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
6K | 9th of October 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
6K | 30th of September 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
6K | 27th of September 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
Ascendis Pharma Forecast Models
Ascendis Pharma's time-series forecasting models are one of many Ascendis Pharma's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Ascendis Pharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Ascendis Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Ascendis Pharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Ascendis shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Ascendis Pharma. By using and applying Ascendis Stock analysis, traders can create a robust methodology for identifying Ascendis entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | (1.78) | (1.87) | |
Operating Profit Margin | (1.71) | (1.79) | |
Net Loss | (1.81) | (1.90) | |
Gross Profit Margin | 0.83 | 0.57 |
Current Ascendis Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Ascendis analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Ascendis analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
0.34 | Strong Buy | 14 | Odds |
Most Ascendis analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Ascendis stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Ascendis Pharma AS, talking to its executives and customers, or listening to Ascendis conference calls.
Ascendis Stock Analysis Indicators
Ascendis Pharma AS stock analysis indicators help investors evaluate how Ascendis Pharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Ascendis Pharma shares will generate the highest return on investment. By understating and applying Ascendis Pharma stock analysis, traders can identify Ascendis Pharma position entry and exit signals to maximize returns.
Begin Period Cash Flow | 444.8 M | |
Long Term Debt | 534.2 M | |
Common Stock Shares Outstanding | 56.3 M | |
Total Stockholder Equity | -145.7 M | |
Tax Provision | 7.3 M | |
Property Plant And Equipment Net | 110.6 M | |
Cash And Short Term Investments | 399.4 M | |
Cash | 392.2 M | |
Accounts Payable | 94.6 M | |
Net Debt | 252.1 M | |
50 Day M A | 132.7972 | |
Total Current Liabilities | 197.3 M | |
Other Operating Expenses | 722.3 M | |
Non Current Assets Total | 122.9 M | |
Non Currrent Assets Other | 2.1 M | |
Stock Based Compensation | 66.7 M |
Complementary Tools for Ascendis Stock analysis
When running Ascendis Pharma's price analysis, check to measure Ascendis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ascendis Pharma is operating at the current time. Most of Ascendis Pharma's value examination focuses on studying past and present price action to predict the probability of Ascendis Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ascendis Pharma's price. Additionally, you may evaluate how the addition of Ascendis Pharma to your portfolios can decrease your overall portfolio volatility.
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |